

EMA/45038/2024

European Medicines Agency decision

P/0037/2024

of 7 February 2024

on the acceptance of a modification of an agreed paediatric investigation plan for abemaciclib (Verzenios), (EMA-002342-PIP01-18-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0037/2024

of 7 February 2024

on the acceptance of a modification of an agreed paediatric investigation plan for abemaciclib (Verzenios), (EMA-002342-PIP01-18-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0124/2019 issued on 17 April 2019, the decision P/0376/2019 issued on 4 December 2019, and the decision P/0440/2021 issued on 29 October 2021 and the decision P/0312/2023 issued on 9 August 2023,

Having regard to the application submitted by Eli Lilly and Company Limited on 10 October 2023 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 19 January 2024, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for abemaciclib (Verzenios), film-coated tablet, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Eli Lilly and Company Limited, 8 Arlington Square West, Downshire Way, RG12 1PU – Bracknell, United Kingdom.

EMA/PDCO/480265/2023
Amsterdam, 19 January 2024

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan 002342-PIP01-18-M04

Scope of the application

Active substance(s):

Abemaciclib

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of Ewing's sarcoma

Pharmaceutical form(s):

Film-coated tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Eli Lilly and Company Limited

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Eli Lilly and Company Limited submitted to the European Medicines Agency on 10 October 2023 an application for modification of the agreed paediatric investigation plan with a waiver as set out in the European Medicines Agency's decision P/0124/2019 issued on 17 April 2019, the decision P/0376/2019 issued on 4 December 2019, and the decision P/0440/2021 issued on 29 October 2021 and the decision P/0312/2023 issued on 9 August 2023.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 20 November 2023.

Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of Ewing's sarcoma

The waiver applies to:

- the paediatric population from birth to less than 1 year of age;
- film-coated tablet, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric investigation plan

2.1. Condition:

Treatment of Ewing's sarcoma

2.1.1. Indication(s) targeted by the PIP

Treatment of relapsed/refractory Ewing's sarcoma in combination with irinotecan and temozolomide

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 year to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

2.1.4. Measures

Area	Description
Quality-related studies	Study 1: Development of 25 mg film-coated tablets for paediatric use.
Non-clinical studies	Not applicable.
Clinical studies	Study 2: Open-label, dose escalation trial to evaluate pharmacokinetics, safety and tolerability of abemaciclib in combination with irinotecan and temozolomide (triplet combination) and abemaciclib in combination with temozolomide (doublet combination) in children less than 18 years of age and weighing at least 10 kg and with body surface area (BSA) being at least 0.5 square meters (m ²) (and adults) with relapsed or refractory solid tumours.

	Study 3: Open-label, randomised, controlled trial to evaluate efficacy, safety, pharmacokinetics and acceptability/palatability of abemaciclib plus temozolomide plus irinotecan compared to temozolomide plus irinotecan in children from 1 year to less than 18 years of age (and adults) with relapsed or refractory Ewing's sarcoma.
Extrapolation, modelling and simulation studies	Study 4: Modelling and simulation study to evaluate the use of the product in the proposed paediatric indication in children from 1 year to less than 18 years of age (and adults) with Ewing's sarcoma.
Other studies	Not applicable.
Other measures	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By September 2028
Deferral for one or more measures contained in the paediatric investigation plan:	No

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of breast cancer

Authorised indication(s):

- for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence
 - Invented name(s): Verzenios
 - Authorised pharmaceutical form(s): Film-coated tablet (tablet)
 - Authorised route(s) of administration: Oral use
 - Authorised via centralised procedure
- for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy
 - Invented name(s): Verzenios
 - Authorised pharmaceutical form(s): Film-coated tablet (tablet)
 - Authorised route(s) of administration: Oral use
 - Authorised via centralised procedure